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Abstract Hutchinson–Gilford progeria syndrome
(HGPS) is a rare and fatal premature ageing disease
in children. HGPS is one of several progeroid
syndromes caused by mutations in the LMNA gene
encoding the nuclear structural proteins lamins A and
C. In classic HGPS the mutation G608G leads to the
formation of a toxic lamin A protein called progerin.
During post-translational processing progerin remains
farnesylated owing to the mutation interfering with a
step whereby the farnesyl moiety is removed by the
enzyme ZMPSTE24. Permanent farnesylation of
progerin is thought to be responsible for the proteins
toxicity. Farnesyl is generated through the mevalonate
pathway and three drugs that interfere with this
pathway and hence the farnesylation of proteins have
been administered to HGPS children in clinical trials.
These are a farnesyltransferase inhibitor (FTI), statin
and a bisphosphonate. Further experimental studies
have revealed that other drugs such as N-acetyl
cysteine, rapamycin and IGF-1 may be of use in
treating HGPS through other pathways. We have
shown previously that FTIs restore chromosome
positioning in interphase HGPS nuclei. Mis-localisa-
tion of chromosomes could affect the cells ability to
regulate proper genome function. Using nine different
drug treatments representing drug regimes in the clinic
we have shown that combinatorial treatments con-
taining FTIs are most effective in restoring specific
chromosome positioning towards the nuclear periph-
ery and in tethering telomeres to the nucleoskeleton.
On the other hand, rapamycin was found to be
detrimental to telomere tethering, it was, nonetheless,
the most effective at inducing DNA damage repair, as
revealed by COMET analyses.
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IGF-1 Insulin-like growth factor 1
mTOR Mammalian target of rapamycin
ROS Reactive oxygen species
Introduction
Genome organisation
Cell nuclei are the organelles that house an organisms’
genome. The chromosomes that make-up the genome
are organised very specifically, with individual chro-
mosomes located within their own individual space,
hence the term ‘‘chromosome territories’’. Given all
the processes the chromosomes have to go through,
such as replication, transcription and repair, it is
predictable that a system by which chromatin avoids
being tangled up in the nucleus would evolve. This is
regulated organisation at the intrachromosomal level
but the cell takes this type of spatial organisation
further to the interchromosomal level by regulating the
specific locations of individual chromosomes radially
with respect to the nuclear edge. In proliferating cells
gene-poor chromosomes are found to be located at the
nuclear periphery with gene-rich chromosomes within
the nuclear interior (Boyle et al. 2001; Bridger et al.
2014). The gene-density distribution of chromosomes
is found in proliferating primary cells but when cells
come out of the cell cycle into quiescence or
senescence chromosomes are rearranged into a size-
correlated distribution with large chromosomes at the
nuclear periphery and small chromosomes in the
nuclear interior (Bridger et al. 2000; Mehta
et al. 2010a).
The reason for this spatial control over chromo-
some territories is not yet entirely clear but it is
postulated to regulate the function of the genome
through position and association of different chro-
matin types with nuclear structures, thus controlling
gene expression (Lemaıˆtre and Bickmore 2015). How
does this specific positioning come about? There are a
number of structures which provide scaffolding to the
genome and anchor chromatin at specific points
around the nucleus through chromatin binding inter-
actions with specific proteins. These include the
nuclear lamina, a mesh-like structure subjacent to
the inner nuclear envelope comprised of A-type and
B-type lamins, the nuclear membrane and proteins
found therein, the nucleolus and other structures found
throughout the nucleoplasm, termed the nucleoskele-
ton (Bourne et al. 2013; Czapiewski et al. 2016).
A-type lamins are involved in many processes
including those associated with genome regulation
and function. We know for example that lamin A is
important in the correct positioning of chromosome
territories in interphase nuclei (Meaburn et al. 2007;
Ondrej et al. 2008; Mehta et al. 2011; Puckelwartz
et al. 2011; Harr et al. 2015), anchoring them at the
nuclear periphery (Kubben et al. 2012; Solovei et al.
2013; Kind and van Steensel 2014) or throughout the
nucleus bound to a nucleoskeleton containing lamin A
(Bridger et al. 1993; Hozak et al. 1995; Broers et al.
1999; Neri et al. 1999; Elcock and Bridger 2008;
Mehta et al. 2008; Barboro et al. 2010). Telomeres
seem to be one of the tethering points for the genome
since telomeric repeats and sequences bind to lamin A
(Shoeman and Traub 1990; Barboro et al. 2003;
Ottaviani et al. 2009; De Vos et al. 2010; Uhlı´rova´
et al. 2010; Das et al. 2013; Saha et al. 2013; Wood
et al. 2014) and interaction of telomeres with defective
lamin A can cause cellular senescence (Cao et al.
2011a). Luderus and colleagues have postulated that
matrix attachment regions (MARs) show an affinity to
tether specific areas of mammalian telomeres to a
nucleoskeleton and have suggested that per kb of
telomeric sequence, that at least one MAR is present
(Luderus et al. 1996). It has been demonstrated that
human telomeres are tethered to the nuclear membrane
by their TTAGGG repeats (de Lange 1992).
Using the genome-wide mapping of protein-DNA
interactions it has been revealed that gene-poor
regions of the genome do indeed interact with the
nuclear lamin proteins present at the nuclear periphery
(Peric-Hupkes and van Steensel 2010; Guelen et al.
2008). These regions have been termed lamina
associated domains (LADs). Indeed, these experi-
ments finally confirm what has been believed for many
decades that nuclear lamin proteins anchor the genome
at the nuclear periphery. However, lamin proteins are
not only found at the periphery of nuclei but are also
found throughout the nucleoplasm in small accumu-
lations (Naetar et al. 2017). The structures that internal
lamin are part of are poorly defined compared to their
well-studied organisation at the nuclear envelope, but
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they are described as being a part of an internal matrix
or nucleoskeleton (Bridger et al. 2007).
Hutchinson–Gilford progeria syndrome:
a laminopathy
The premature ageing syndrome Hutchinson–Gilford
progeria syndrome (HGPS) is a severe childhood
disease that leads to an early death usually from heart
attacks and strokes as a teenager (Ahmed et al. 2017).
HGPS is normally caused by the silent mutation
G608G in the LMNA gene, encoding for the A-type
lamins—nuclear lamins A and C. This mutation
creates a splice variant leading to a new protein,
progerin, which is a 50 amino acid truncated version of
lamin A. This protein cannot be processed correctly.
Progerin is toxic to cells since it retains a farnesyl
group which affects its incorporation into the nuclear
envelope and ultimately its functionality. Progerin
negatively affects the disassembly of the nuclear
envelope at the beginning of mitosis as it remains with
the membrane material rather than being released and
becoming soluble during mitosis (Wu et al. 2014).
Since A-type lamins have been described as chromatin
binding proteins HGPS and other laminopathies, have
become a model to study genome organisation and the
involvement of lamin proteins. Indeed, we have
demonstrated, painting whole chromosomes in inter-
phase nuclei, that genome organisation and chromo-
some positioning are affected in classic HGPS
fibroblasts such that chromosomes normally found at
the nuclear periphery in normal proliferating fibrob-
lasts are now found towards the nuclear interior
(Meaburn et al. 2005; Meaburn et al. 2007; Mehta
et al. 2011). Further, studies assessing the chromoso-
mal sequence attachment at the nuclear lamina also
show alterations in genome organisation when com-
pared to normal cells (Kubben et al. 2012).
We initially proposed that the lamin A mutation
must have affected the anchorage of the gene-poor
chromosomes with progerin preventing them attach-
ing to the peripheral nuclear lamina and therefore
finding docking elsewhere in the nucleus. However,
this interpretation is too simple because chromosomes
such as the X chromosome territories are still in
position at the nuclear edge. It was then thought that
these cells mirrored senescent cells with respect to
chromosome positioning since they are derived from
patients with premature ageing syndrome. When the
position of chromosome 10 was analysed it became
clear that the HGPS cells, even though they are
proliferating, have a signature of chromosome loca-
tion common to quiescent human dermal fibroblasts.
This is because chromosome 10 has a peripheral
location in quiescent primary fibroblast nuclei and not
in senescent cells, implying that genome organisation
is not similar to aged senescent cells but pathways
linking proliferation with lamins have become dis-
connected or unregulated (Mehta et al. 2011; Bridger
et al. 2014). The association of LMNA mutations with
altered chromosome territories was shown in LMNA
mutant fibroblasts as chromosome 13 was displaced to
the nuclear interior in LMNA E161 K mutants cells
(Mewborn et al. 2010), whereas chromosome 13 was
shown positioning against the nuclear membrane in
LMNA D596 N mutant cells (Puckelwartz et al. 2011)
and in S143F and E145 K mutations of LMNA (Bercht
Pfleghaar et al. 2015; Taimen et al. 2009, respec-
tively). Most telomeres avoid the nuclear periphery
and are dispersed throughout the nuclear interior,
suggesting a more specific role for intranuclear lamins
in tethering telomeres (Shimi et al. 2008). A reposi-
tioning of telomere localization was observed towards
the nuclear periphery in cells lacking A-type lamins,
suggesting an active role of A-type lamins in the
positioning of telomeres in the nuclear interior (Gon-
zalez-Suarez et al. 2009).This reveals two things about
HGPS—that the progerin with its uncleaved farnesyl
group has uncoupled chromosome behaviour from the
cell cycle and that HGPS has nuclei that resemble
quiescent rather than senescent cells (Bridger et al.
2014).
Drug treatments for HGPS
There are now a number of drugs that have been
investigated as treatments for HGPS both in the clinic
and in the laboratory. These include farnesyl trans-
ferase inhibitors (FTIs) that block the transfer of the
farnesyl group rendering a truncated lamin A protein
without the farnesyl groups. Subsequently, other drugs
that work in the mevalonate pathway the statin—
pravastatin and the bisphosphonate zoledronic acid
were investigated. Drug trials were conducted in the
US that were purely FTI—Lonafarnib initially (Gor-
don et al. 2012) and another in Europe where
pravastatin and zoledronic acid were used in combi-
nation (Blondel et al. 2014). A second clinical trial in
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the US was initiated using FTI, plus statin and the
bisphosphonate (Gordon et al. 2014). Further investi-
gations in a number of laboratories have suggested
other drugs/treatments that would/could treat HGPS—
these include the N-acetyl cysteine, free radical
scavenger (Richards et al. 2011), rapamycin—the
new anti-ageing treatment (Cao et al. 2011b; Cenni
et al. 2012; Graziotto et al. 2016; Evangelisti et al.
2016), and IGF-1 (Marin˜o et al. 2010).
In the past we have performed genome organisation
studies with FTI with and without geranylgeranyl-
transferase inhibitors (GGTI) (required as cells can
compensate for the lack of farnesylation with gerany-
lation). Using FTI singularly and in combination with
GGTI we have revealed that these drugs do indeed
correct chromosome positioning—allowing gene-
poor chromosomes such as chromosomes 13 and 18
to be located at the nuclear envelope in proliferating
HGPS cells (Mehta et al. 2011). Implying that the
farnesyl group itself is causing the uncoupling of
pathways. However, we have not tested any of the
other employed or potential drugs on genome organ-
isation until now. Furthermore, we have gone further
than before and analysed other aspects of genome
intra-nuclear organisation for nine different drug
regimes. Using HGPS cells with the classical G608G
mutation we have analysed the effect of specific drugs
on the HGPS phenotype including chromosome
territory positioning, telomeric attachment to the
nucleoskeleton in DNA Halo preparations and the
extent of DNA damage and repair markers through
immunofluorescence staining and COMET analysis.
Materials and methods
Cell culture
An HGPS cell-line derived from AG01972 (14 years
old female primary HGPS) was obtained from Coriell
Cell Repositories (New Jersey, USA) at the earliest
passage available and passaged twice weekly at a
specified density. This HGPS cell-line proliferated
well, with a Ki67 index[ 50% initially. Samples
were taken for all assays at similar times. The 2DD
normal dermal fibroblast cell line was used as a control
at passage numbers between 7 and 15 (Bridger et al.
1993). This line has a normal karyotype. These cell
lines were cultured in T75 tissue culture flasks (Fisher,
UK) in Dulbecco’s Modified Eagles Medium
(DMEM) (Invitrogen, UK), with the following addi-
tives: 15% foetal bovine serum (FBS) (Invitrogen),
2% (v/v) streptomycin and penicillin antibiotics
(Invitrogen) and 200 mM L-glutamine (Invitrogen).
The cells were maintained at 37 C temperature, in a
humidified atmosphere containing 5% CO2. Cells were
washed with 3 ml of versene (NaCl 0.8% (w/v), KCl
0.02% (w/v), Na2HPO4 0.0115% (w/v), KH2PO4
0.02% (w/v), 0.2% EDTA (w/v) (Sigma Aldrich)).
Followed by 3 ml diluted solution of 0.25% trypsin
(Invitrogen): versene (1:10, v: v) for up to five
minutes. As soon as all the cells were detached from
the flasks’ bottoms, the effect of trypsin solution was
neutralized by adding an equal amount of DMEM
medium to the dishes. The final suspension was
centrifuged at 300–400 g for 5 min. The cells were
then seeded in T75 flasks at a density of 5 9 105/flask.
Drug treatments
The drugs employed in this study were FTI-277,
Pravastatin, Zoledronic acid, Rapamycin, Insulin-like
growth factor 1, N-acetyl-L-cysteine and GGTI-2133
and were all obtained from Sigma Aldrich, UK. Drugs
were added to the media and incubated for fixed
periods of time. The final concentration and duration
of drug treatments were: FTI-277—2.5 lM for 48 h
(Mehta et al. 2011), pravastatin—1 lM for 24 h
(Varela et al. 2008), zoledronic acid—1 lM for
24 h, rapamycin—10 nM for 24 h (Cao et al.
2011b), insulin-like growth factor 1—50.0 ng/mL
for 24 h (Marin˜o et al. 2010), N-acetyl-L-cysteine—
20 lM for 1 h (Richards et al. 2011), FTI-277 and
GGTI-2133—both 2.5 lM for 48 h) (Mehta et al.
2011; Kieran et al. 2007), pravastatin and zoledronic
acid—both 1 lM for 24 h (Varela et al. 2008) and
FTI-277—2.5 lM for 48 h, pravastatin and zole-
dronic acid—both 1 lM for 24 h.
Two-dimensional fluorescence in situ
hybridisation
Cells were harvested by incubation 0.25% trypsin in
versene and centrifuged at 300–400 g for 5 min, and
then the supernatant was removed. Harvested cells
were treated with a hypotonic solution (0.075 M KCl)
for 15 min at room temperature, to swell the cells. The
cell suspension was centrifuged at 300 g for 5 min
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using a bench top centrifuge. The cells were fixed by
removing the supernatant and re-suspending the cell
pellet in ice-cold methanol: acetic acid (3:1 v/v),
added drop-wise to the cells with gentle agitation. The
cells were incubated at 4 C for at least 1 h and then
the fixation step was repeated 4-5 more times before
storage or - 20 C. The cells were then dropped onto
damp SuperFrostTM slides from a height, and air dried
and aged at 70 C for 1 h or for 2 days at room
temperature. The aged slides were passed through an
ethanol row of 70, 90 and 100% ethanol for 5 min in
each solution, followed by air drying. The slides were
then incubated in denaturation solution (70% {v/v}
formamide, 2X SSC, pH 7.0) at 70 C for 5 min. The
slides were immediately plunged into ice-cold 70%
ethanol for 5 min and then again passed through the
ethanol row (90 and 100% ethanol). The slides were
air dried and kept warm until hybridization with the
probe.
The chromosome templates 18 and X were made in-
house by amplifying flow sorted chromosomes by
degenerate oligonucleotide primed polymerase chain
reaction (DOP-PCR). These chromosome templates
were labelled with biotin-16-dUTP (Roche). The
slides were allowed to hybridise with the probe in a
humid chamber at 37 C for at least 18 h, washed and
mounted in Vectashield (Vectalabs) mounting med-
ium containing DAPI.
Indirect immunofluorescence
In order to distinguish proliferating cells from non-
proliferating cells, 2D-FISH was combined with
indirect immunofluorescence staining for antigen
pKi-67. PKi-67 is a nucleolar antigen that is only
present in cells in proliferative cell cycle (Gerdes et al.
1983). The coverslips from the FISH experiments
were removed by placing slides in 19 PBS solution for
30 min on a shaker until the coverslips detach. The
slides were incubated 100 ll of rabbit primary anti-
pKi-67 (DAKO, A0047) (1:30 dilution in 1% NCS/
PBS v/v) and placed in an humidified chamber either
for 2–3 h at room temperature or overnight at 4 C,
followed by 27 washes in 19 PBS. Subsequently,
fluorochrome-conjugated secondary antibody, the
swine anti-rabbit (TRITC) antibody (DAKO, R0156)
diluted with 1% FBS in 19 PBS was added to the
slides. Cells were incubated in the dark for either
30 min at 37 C or 1 h at room temperature. The cells
were washed 27 times in 19 PBS followed by a final
wash in double distilled water. Mouse monoclonal
anti-human lamin A/C (Novocastra) diluted 1:10 with
FITC-conjugated secondary antibody (diluted 1:30
(Dako), was used to reveal A-type lamins and
Vectashield containing DAPI (Vector Laboratories)
was added to each slide and the coverslip.
For the cH2AX DNA damage assay, cells were
washed 15 min two times with PBS. 100 ll of c-
H2AX antibody (dilution of 1:500 with 1% PBS/FCS,
Upstate) was added to the slides for 1 h at room
temperature then after which slides were washed in
PBS for 15 min. 100 ll of goat anti-mouse (FITC)
(diluted 1:64 with 1% PBS/FCS, Sigma-F9006) sec-
ondary antibody was added for 1 h at room temper-
ature and then rinsed with PBS for 15 min and
mounted in Vectashield.
DNA halo preparations
Cells were grown for 2 days on SuperFrost slides
(Fisher, UK) in QuadriPERMTM (Sarstedt, Germany)
chambers, at a starting density of 1 9 105. The
medium was removed and the slides were washed 3
times with 19 PBS. Slides were then placed in Coplin
jars, on ice, containing CSK buffer (10 mM Pipes pH
7.8, 100 mM NaCl, 0.3 M sucrose, 3 mM MgCl2,
0.5% (v/v) Triton-X 100) for 15 min. The slides were
then washed again three times in 19 PBS. The slides
were placed in extraction buffer (2 M NaCl, 10 mM
Pipes pH 6.8, 10 mM EDTA, 0.1% (w/v) digitonin,
0.05 mM (v/v) spermine, and 0.125 mM (v/v) sper-
midine) for 4 min. The slides were then rinsed
consecutively in 109 PBS, 59 PBS, 29 PBS and
19 PBS, for 1 min each. The slides were taken
through an ethanol series of 10, 30, 70 and 95% (v/v),
respectively. The slides were air dried and stored. Fifty
images of cell nuclei for each condition were taken at
9100 magnification using a Zeiss Axiovert 200 M
with a Plan-NEOFLUAR 9100/1.30 objective lens
(Carl Zeiss, Germany) and high resolution digital
camera (AxioCam b/w, Carl Zeiss, Germany) under
the control of Axiovision software (Carl Zeiss).
Measurements for area of residual nucleus and extent
of halo were measured with ImageJ software, and the
ratio of the DNA halo to residual nucleus was
calculated and plotted (Elcock and Bridger 2010;
Clements et al. 2016).
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For bromo-deoxy uridine incorporation into the
genome in order to visualise proliferating cells,
the medium was removed and replaced with medium
containing BrdU and FrdU (3 lg/ll) (Sigma Aldrich).
After 24 h, the media was removed, cells were washed
once with medium (10% NCS) and then re-fed with
medium (10% NCS). Following an additional 24 h,
the slides were taken through the DNA halo prepara-
tion. Slides were washed 3 times in PBS and incubated
at room temperature for 1 h in BrdU mouse anti-
human diluted 1:100 (BD Pharmingen). Cells were
then washed 3 times in PBS and incubated at room
temperature for 1 h in donkey anti-mouse Cy3 diluted
1:100 (Jackson Laboratory). Following 3 more washes
with PBS, slides were mounted with Vectashield
(Vector Laboratories) containing DAPI.
Telomere PNA FISH
In order to detect telomeres on the DNA halo
preparations, a Telomere PNA FISH/Cy3 kit (Dako)
was used following a protocol under the manufac-
turer’s instructions. Unless otherwise stated, the
protocol was performed at room temperature. The
DNA halo slides were immersed in tris-buffered saline
(TBS, pH 7.5) for 2 min in 3.7% formaldehyde (in
TBS, v/v). The slides were then washed in TBS twice
for 5 min each. They were then immersed in pre-
treatment solution for 10 min and subsequently
washed twice with TBS for 5 min. The slides were
then run through an ice cold ethanol series consisting
of 70, 85 and 95% (v/v) ethanol for 2 min at each
concentration. Slides were air dried and 10 ll of
Telomere PNA Probe/Cy3 was added to each slide.
The coverslip was replaced and then the slides were
placed in a pre-heated oven at 80 C for 5 min and
then in the dark for approximately 1 h. The coverslips
were removed by immersing the slides in the Rinse
Solution for 1 min and then in Wash Solution for
5 min at 65 C. The slides were subjected to a further
ice-cold ethanol series (70, 85 and 95% (v/v)) for two
minutes at each concentration, and then air dried.
Slides were mounted with Vectashield (Vector Lab-
oratories) containing DAPI. Images were captured at
9100 magnification using a Zeiss Axiovert 200M with
a Plan-NEOFLUAR 9100/1.30 objective lens (Carl
Zeiss, Germany) and high resolution digital camera
(AxioCam b/w, Carl Zeiss, Germany) under the
control of Axiovision software (Carl Zeiss). The
proportions of telomeres within residual nuclei for
each treatment were counted and expressed as a
percentage of the total telomeres.
Microscopy and data analysis
For chromosome positioning analyses slides were
examined using a Zeiss Axiovert 200M with a Plan-
NEOFLUAR 9100/1.30 objective lens (Carl Zeiss,
Germany) and high resolution digital camera (Ax-
ioCam b/w, Carl Zeiss, Germany) under the control of
AxioVision software (Carl Zeiss). Nuclei were
selected randomly by following a rectangular scan
pattern, and grey-scale images of these nuclei with the
DAPI signal pseudo-coloured in blue and biotin-
streptavidin signal pseudo-coloured in green were
captured. At least 50–60 images per slide were taken
and converted into TIFF or PICT format. The images
were passed through a bespoke erosion analysis script
using IPLab Spectrum software (a kind gift of Prof
Wendy Bickmore, Edinburgh). Similar scripts have
been devised and can be found in the literature from
the laboratories of Profs Eric Schirmer, BJ Rao and
Christopher Eskiw (Robson et al. 2016; Mehta et al.
2013; Gillespie et al. 2015). The script is devised to
divide each captured nucleus into 5 concentric shells
of equal area, the first shell starting at the periphery of
the nucleus going to the interior of the nucleus (5th
shell). The script measures the pixel intensity of DAPI
and the chromosome probe in the five shells. The
background from the FISH signal was removed by
subtracting the mean pixel intensity within the
segmented nucleus. The probe signal was normalised
by dividing the percentage of the probe by the
percentage of DAPI signal in each shell. The normal-
ized proportion of probe was calculated in all 5 shells
for at least 50 nuclei (Croft et al. 1999; Clements et al.
2016). The data were plotted as bar charts.
Statistical analysis
Values are expressed as averages ± SEM, and n
represents the number of experiments analysed. Indi-
vidual treatments were compared using either two-
tailed unpaired t-tests or one-way ANOVAs with
Tukey’s post hoc multiple comparison tests where
appropriate, and significance was taken as P B 0.05.
The level of significance is indicated as: * P B 0.05,
**P B 0.01, ***P B 0.001 and ****P B 0.0001.
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Analysis was performed using Graphpad Prism 6.0 for
Windows package.
Comet assay
To estimate endogenous levels of DNA damage in
treated and untreated progeria cells, the single cell gel
electrophoresis (alkaline comet) assay was used.
Comet assays were performed using an Fpg FLARETM
Assay Kit according to the manufacturer’s instructions
(Trevigen). Prepared slides were placed in a cooled
electrophoresis tank and electrophoresis was per-
formed at 1 V/cm for 30 min. Slides were washed
twice in dH2O for 5 min each, then in 70% ethanol for
5 min before air drying to bring all cells into a single
focal plane. SYBR Green was added to each sample
and incubated at room temperature in the dark for
30 min. Excess solution is removed and the slides
again left to air-dry completely. Slides were viewed
and analysed with a 209 objective mounted on a Zeiss
Axioplan2 microscope controlled by the Metafer
MetaCyte cometscan software. Estimates of DNA
damage level in each cell were determined using
Comet tail moments (% of DNA in tail 9 tail length in
lm) of at least 100 cells per slide in triplicate for each
sample automatically calculated by the cometscan
analysis plug-in for the Zeiss MetaCyte software.
Field emission scanning electron microscopy
Cells were grown on ethanol-sterilised
5 mm 9 5 mm silicon chips (Agar Scientific Ltd) in
6-well plates, each well contained 2 silicon chips and
was seeded with * 0.5 to 1 9 105 cells. Since the
Y259X cells did not grow well on plain silicon chips,
the chips used for this cell line were coated with
0.01 mg/ml poly-D-lysine (Sigma) overnight and then
were left to dry for 2 h before use. The chips were
removed at different stages throughout both extraction
procedures and then placed and stored in fixative (3%
(v/v) glutaraldehyde, 1% (w/v) PFA in 0.1 M sodium
cacodylate buffer). The chips were washed in 0.2 M
sodium cacodylate buffer and incubated in 1% (w/v)
osmium tetroxide (OsO4) for 15 min at room temper-
ature. Following this, the chips were placed in distilled
water and taken straight-through an ethanol row of 50,
70, 95 and 100% (v/v). Specimens were critical point
dried with CO2 using a Bal-Tec CPD 030 (BAL-TEC)
machine. A Cressington Coating System 308R (Ted
Pella, Inc) was then used to sputter coat the chips with
either platinum or chromium (1–3 nm). The speci-
mens were viewed using a Hitachi Model S-5200
feSEM (Hitachi High-Technologies) at various accel-
erating voltages.
Results
Which drug treatments restore chromosome
territory positions in HGPS fibroblasts?
In previous studies we have shown that chromosome
18, located at the nuclear periphery in normal control
proliferating fibroblasts, is mis-localised to the nuclear
interior in four different proliferating HGPS cell lines
(Meaburn et al. 2007; Mehta et al. 2010a, 2011). Our
chromosome positioning is analysed in flattened
fibroblast nuclei using 2D-FISH, whole chromosome
painting probes and a bespoke erosion analysis (Croft
et al. 1999; Clements et al. 2016). The erosion analysis
script delineates the imaged nuclei and then erodes in
creating five shells of equal area, with shell 1 being the
most peripheral and shell 5 the most internal. The
intensity of the signal from the DNA stained with
DAPI and the chromosome is recorded, the data are
normalised by dividing the chromosomal signal by the
DNA signal for each shell in each nucleus. These data
are plotted as bars to visualise the distribution of
chromosomal signal in an average of 50 nuclei. Since
we have shown that small chromosome territories such
as 18 are repositioned to the nuclear interior in non-
proliferating cells (Bridger et al. 2000; Mehta et al.
2007, 2010a) it is imperative to combine the FISH
with a marker for proliferation, such as staining for the
nucleolar antigen Ki67. Thus this positioning assay of
chromosome location, combined with Ki67, permits
us to determine if the different drug regimens we have
selected can restore genome organisation in prolifer-
ating HGPS cells. X chromosome territories provide a
control for a chromosome that does not change
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location in HGPS cells (Meaburn et al. 2007; Mehta
et al. 2010a, 2011). Figure 1 displays representative
images for X chromosome positioning within classical
HGPS fibroblasts treated with the nine different drug
treatments. Upon using the erosion analysis for
proliferating HGPS cells only (i.e. Ki67 positive) we
found that indeed as in our other studies chromosome
X territories were predominantly found at the periph-
ery of the nuclei in all situations to varying degrees
(Fig. 1a–h), with maximum fluorescent chromosome
signal in both shells 1 and 2. The only treatments that
enhanced the skew of the graphs more towards shell 1
(i.e. the nuclear periphery) significantly were drug
treatments containing FTI i.e. FTI alone (Fig. 1b), FTI
and GGTI (Fig. 1h) and FTI with pravastatin and
zoledronic acid (Fig. 1j).
Figure 2 reveals the normalised distribution of the
fluorescent signal for chromosome 18 territories in the
treated and untreated HGPS cells. Most interestingly
we have confirmed our findings from before that FTI is
the most successful drug when looking to correct
chromosome positioning. Again only drug treatments
containing FTI resulted in a significant reorganisation
of the genome, as evidenced by the repositioning of
the chromosome 18 territories towards the nuclear
periphery. These were FTI-277 ? GGTI-2133
(Fig. 2h) and FTI-277 ? pravastatin ? zoledronic
acid (Fig. 2j). FTI alone shifted the distribution of
the chromosome territories towards the nuclear
periphery but was not significant at the 99.9%
confidence interval (Fig. 2b), whereas it has been in
our other study (Mehta et al. 2011). All other drug
treatments i.e. pravastatin alone (Fig. 2c), zoledronic
acid alone (Fig. 2d), rapamycin (Fig. 2e), IGF-1
(Fig. 2f) and NAC (Fig. 2g) did not induce any
repositioning of chromosome 18 back to the nuclear
periphery. Thus it seems that the combinatorial drug
treatments containing FTI are the most effective at
restoring genome organisation. Given that neither
exposure to pravastatin nor zoledronic acid treatments
have restored normal chromosome positioning it has
to be FTI that is the active component, perhaps
allowing an unfarnesylated progerin to make an
appropriate lamina connection, presumably through
LADs.
Using DNA halo preparations to analyse
alterations in genome interaction with nuclear
structure before and after drug treatments in HGPS
cells
DNA halo preparations have been used for some time
now to study interactions of the genome with the
nucleoskeleton (Wilson et al. 2016). They are pre-
pared from cells grown on glass, permeabilised with
detergent and digitonin and extracted with high salt
DNA halo extraction buffer. The idea being that DNA
not attached to nuclear structures will extrude beyond
the nuclear envelope out of the permeabilsation holes
and form a halo of DNA around a residual nucleus.
Figure 3 demonstrates DNA halo preparations
whereby a range of different analyses can be per-
formed to analyse the genomes’ relationship with the
nucleoskeleton within the residual nuclei which is the
DNA that is tightly bound to nucleoskeleton. It is
possible to visualise whole chromosomes (Fig. 3a)
and individual gene loci (Fig. 3b) and telomeres
(Fig. 3c, j–m) when performing Halo-FISH. Indirect
immunofluorescence is also possible alone and in
combination with FISH. Figure 3b, j and k reveal
nucleoli within residual nuclei as delineated by anti-
Ki67 antibodies. When DNA halo preparations are
bFig. 1 Position of chromosome X within HGPS fibroblast
nuclei before and after drug treatments. HGPS fibroblasts,
treated and untreated were fixed and subjected to FISH using
whole chromosome arm painting probes specific for chromo-
some X. Images were captured at 9100 magnification.
Positional information for the chromosome X territories within
interphase nuclei was ascertained through erosion analysis
revealing the proportion of chromosome signal (%), normalised
by the DAPI signal, over five concentric shells of equal area,
starting at the nuclear periphery (shell 1) to the nuclear interior
(shell 2). These data are displayed graphically as bar charts with
the x-axis displaying the erosion shells from 1 to 5 (left to right.
The y-axis displays % normalised chromosome signal. Panels
are as follows a untreated, b FTI-277, c pravastatin, d zoledronic
acid, e rapamycin, f IGF-1, gN-acetyl-L-cysteine, h FTI-277 and
GGTI-2133, i pravastatin and zoledronic acid and j FTI-277,
pravastatin and zoledronic acid. Representative images the
interphase nuclei are displayed to the right of each graph. DAPI
(blue) is used as a counterstain to delineate the nuclei and the
chromosome 18 territories are revealed in green. Scale
bar = 10 lM
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subjected to feSEM, it is possible to visualise the
residual nuclei (Fig. 3d) and the surrounding DNA
halo (Fig. 3e), very clearly. It is also possible to use
the DNA halo preparations to ask specific and
quantifiable questions about nuclear structure and an
interacting genome relationship. Figure 3h and i
display anti-A-type lamin staining in a control and
an HGPS nucleus, respectively. After extraction in the
DNA halo preparation some of the A-type lamins have
been extracted from the nuclear envelope, leaving/
revealing an internal veil of A-type lamins (Fig. 3h, i).
Gerdes and colleagues demonstrated that although
transcriptionally inactive sequences have loose inter-
actions with the nucleoskeleton, transcriptionally
active DNA has a much tighter connection with the
nucleoskeleton (Gerdes et al. 1994). Similar results
were revealed by Croft et al. that gene-dense human
chromosome 19 was much more tightly associated
with the nucleoskeleton than gene-poor human chro-
mosome 18 (Croft et al. 1999).
Performing FISH on these preparations, named
HALO-FISH using telomere specific probes can
delineate specific DNA sequences (Volpi and Bridger
2008; de Lange 1992). It is believed that the associ-
ation of telomeres with the nucleoskeleton is disrupted
in HGPS (Elcock and Bridger 2010). Figure 3j and k
reveal telomere distribution in DNA halos of prolif-
erating (Ki67 positive) control and HGPS cells,
respectively. Figure 3l and m display the telomere
distribution within senescent control and HGPS
nuclei, respectively. In the HGPS cells it is noticeable
that there are more telomeres (green foci) away from
the residual nuclei in the surrounding DNA halos
(Fig. 3k and m). Indeed, it was demonstrated that an
interaction between a telomere-binding protein, TRF-
2 and lamin A/C is disrupted in HGPS which gives rise
to telomere instability (Wood et al. 2014).
To date, there are no studies looking at the
interactions between the genome and the nucleoskele-
ton in HGPS in the context of proposed drug
treatments. To address this gap of knowledge, this
investigation utilises the DNA halo assay to evaluate
the efficacy of these drugs in restoring these interac-
tions. Thus, we have perfected DNA halo extractions,
combined with FISH, to analyse the association of the
nucleoskeleton with the specific regions of the genome
(Elcock and Bridger 2010). A high salt DNA halo
extraction buffer is used to release unbound DNA
from cell nuclei. After fixation 2D-FISH is performed
to reveal specific genomic sequences (Elcock and
Bridger 2010; Clements et al. 2016). Using simple
image analysis through ImageJ FISH signals can be
assigned to the residual nucleus i.e. they are bound to
the nucleoskeleton and are not extractable or they are
located in the nuclear halo and they are extracted and
therefore not bound tightly to the nucleoskeleton.
Averaged measurement of the area of the residual
nuclei in untreated 2DD normal fibroblasts (Fig. 4a)
was found to be 410.5 ± 19.7 lm2 (n = 50). However
in the AG01972 HGPS fibroblasts, the averaged
residual nuclear area was significantly reduced to half
at 266.4 ± 10.4 lm2 (n = 50, p\ 0.0001) (Fig. 4b).
Strikingly, most of the drug treatments were found to
increase the residual nuclear size (Fig. 4, Supplemen-
tary Table 1) to be statistically similar to the normal
control cells, apart from any treatment containing
zoledronic acid (Fig. 4c, h and i, Supplementary
Table 1). Moreover, upon treatment of zoledronic acid
in 2DD cells, the size of the averaged residual nuclei
significantly decreased (p\ 0.001) (Supplementary
Fig. 1). This result suggests that zoledronic acid may
cFig. 2 Position of chromosome 18 within HGPS fibroblast
nuclei before and after drug treatments. HGPS fibroblasts,
treated and untreated were fixed and subjected to FISH using
whole chromosome arm painting probes specific for chromo-
some 18. Images were captured at 9100 magnification.
Positional information of the chromosome 18 territories within
interphase nuclei was ascertained through erosion analysis
revealing the proportion of chromosome signal (%), normalised
by the DAPI signal, over five concentric shells of equal area,
starting at the nuclear periphery (shell 1) to the nuclear interior
(shell 2). These data are displayed graphically as bar charts with
the x-axis displaying the erosion shells from 1 to 5 (left to right.
The y-axis displays % normalised chromosome signal. Panels
are as follows a untreated, b FTI-277, c pravastatin, d zoledronic
acid, e rapamycin, f IGF-1, gN-acetyl-L-cysteine, h FTI-277 and
GGTI-2133, i pravastatin and zoledronic acid and j FTI-277,
pravastatin and zoledronic acid. Representative images the
interphase nuclei are displayed to the right of each graph. DAPI
(blue) is used as a counterstain to delineate the nuclei and the
chromosome 18 territories are revealed in green. Scale
bar = 10 lM
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have a detrimental effect on the genome and its ability
to bind the nucleoskeleton in HGPS and 2DD fibrob-
lasts or it becomes broken releasing more DNA from
the DNA halos.
The proportion of telomeres remaining
within the residual nucleus after a DNA halo
preparation
Figure 5 displays the data for telomere location within
control primary (Fig. 5a) and HGPS (Fig. 5b) fibrob-
lasts halo preparations before and after drug treat-
ments. The telomeres are revealed using a commercial
PNA-telo probe that hybridises to telomere repeats.
The representative images show the difference
between the telomere locations for the HGPS cell line
compared to the control cell line. Most telomeres are
located within the residual nucleus in the control
fibroblasts subjected to extraction. This is in agree-
ment with other studies that conclude that all telom-
eres should be, and on the whole are, attached tightly
to structures within the nucleus. However, in the
HGPS cells many of the telomere signals (20%) are
found outside of the residual nucleus in the surround-
ing DNA halo. The actual mean proportion of
telomeres remaining within the residual nuclei of
2DD fibroblasts was found to be 93.9 ± 0.5%
(Fig. 5a, Supplementary Table 2). However, in
AG01972 HGPS fibroblasts, the proportion of interior
telomeres was found only to be 80.0 ± 2.0%, which is
significantly less than the control (p\ 0.0001). When
the selected drug treatments are used all treatments
bring the number of telomeres within the residual
nucleus back to a normal level (Supplementary
Table 2), except for FTI alone which only partially
rescues (Fig. 5c) the mean proportion of interior
telomeres to 87.9 ± 1.0% (n = 37), which is signif-
icantly greater than untreated AG01972 fibroblasts
(P\ 0.0001) but is still significantly different from
the normal control cells (P\ 0.001). Rapamycin
treatment however, reduces the percentage of telom-
eres within the residual nucleus still further to 76%,
but is not found to be significantly different
(P\ 0.0001) from the untreated HGPS cells.
DNA damage and drug treatments in HGPS
HGPS cells display DNA damage foci consistently
(Liu et al. 2005). The effect of specific compounds on
the presence of DNA damage in human HGPS
fibroblasts has only been performed previously with
FTIs (Liu et al. 2006; Constantinescu et al. 2010) and
N-acetyl-L-cysteine (Richards et al. 2011) within the
panel of drug treatments we have selected. Figure 6
displays representative images of the fraction of cells
that contain no, 1–2 or multiple cH2AX foci. The
results reveal that untreated HGPS fibroblasts exhibit a
significantly higher proportion of multiple foci
(59.2 ± 12.2%) and a significantly lower proportion
of negative staining (no foci) (27.7 ± 8.0%) com-
pared to untreated 2DD control fibroblasts
(0.3 ± 0.3%, P B 0.0001 and 98.6 ± 0.7%, n = 3,
P B 0.0001 respectively) (Fig. 6). The effect on the
cFig. 3 A range of images displaying characteristics of DNA
halo preparations. Nucleoskeleton-associated DNA is anchored
to the residual nucleus, while extracted, non-associated DNA
forms the faint halo surrounding the structure. DNA has been
stained using DAPI and can be seen in blue. Panel a displays a
representative DNA Halo preparation that has been subjected to
immuno-FISH using a painting probe for chromosome 17 (red)
and the proliferation nucleolar marker pKi67 (green). Panel
b displays another DNA Halo preparation with again the
nucleolar proliferation marker pKi67 in green and CCND1 gene
loci in red. Panel c is a DNA Halo preparation displaying a
proliferating cell that has incorporated bromo-deoxy-uridine
during DNA replication (red), DNA in blue and telomere
sequences revealed with a PNA-telo probe in green. Panel
d shows a residual nucleus surrounded by a halo of DNA
visualised by feSEM. The morphology of the residual nucleus
(RN) and surrounding DNA halo (DH) Magnification = 6 k
scale bar = 2.5 lm. Panel e displays extracted, supercoiled
DNA (white arrowheads) within the DNA halo, scale bar
300 nm. Panels f and g are representative control and HGPS
fibroblasts with lamin A revealed by indirect immunofluores-
cence in unextracted cells, respectively and lamin A distribution
present in residual nuclei of DNA halo preparations in extracted
cells (h and i). Panels j–m display representative images of
DNA halo preparations with telomeres in green in proliferating
control and HGPS fibroblasts (j and k, respectively) revealed
with anti-Ki67 staining (red) and senescent control and HGPS
fibroblasts (l and m, respectively). Note in the HGPS cells
telomere signals are located out with the residual nuclei. Scale
bars in panels b and f = 10 lm
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Fig. 4 Alterations in size of residual nuclei in DNA Halo
preparations of HGPS fibroblasts before and after drug
treatments. Images of fixed HGPS DNA halos stained with
DAPI taken at 9100 magnification were analysed by ImageJ
delineating the residual nuclei and the entire DNA halo. The
data displayed in this figure reveals the area measurement of the
residual nuclei (x-axis). Results for the treatments are a FTI-
277, b pravastatin, c zoledronic acid, d rapamycin, e IGF-1, f N-
acetyl-L-cysteine, g FTI-277 and GGTI-2133, h pravastatin and
zoledronic acid and i FTI-277, pravastatin and zoledronic acid.
Error bars represent ± SEM
123
592 Biogerontology (2018) 19:579–602
presence of DNA damage foci is dramatically differ-
ent with the different drug treatments. FTI shows no
statistical change. On the other hand pravastatin
treatment reveals a significant reduction in the fraction
of cells displaying multiple foci (18.9 ± 11.2%,
n = 3) as well as a significantly higher proportion of
cells displaying negative staining (74.3 ± 12.2%)
compared to untreated HGPS fibroblasts (Fig. 6b).
Interestingly, the other drug that interferes with the
mevalonate pathway, zoledronic acid, shows a trend
towards an increase in the number of cells displaying
multiple cH2AX foci (73.8 ± 5.9%, n = 3) and a
lower proportion of negative staining (no foci)
(12.6 ± 3.6%, n = 3) compared to untreated HGPS
fibroblasts, although statistically insignificant at the
99.9% confidence interval (Fig. 6c) but is worrying
nonetheless. IGF-1, like zoledronic acid, results in an
apparent increase in cells displaying DNA damage but
is also not significant. However, both rapamycin and
NAC significantly and dramatically reduce the amount
of cells displaying cH2AX foci (Fig. 6d). These
results for rapamycin and NAC are not unexpected
since they have been shown previously to reduce DNA
damage in HGPS cells (Chen et al. 2011; Saha et al.
2014; Richards et al. 2011).
The combinatorial drug treatments are interesting
since FTI-277 and GGTI-2133 together (Fig. 6g), do
not lead to a significant reduction in cH2AX foci.
Neither does pravastatin and zoledronic acid together
(Fig. 6h) which is not surprising as their actions may
cancel each other out since pravastatin performs well
and zoledronic acid may induce more damage. Adding
FTI to this combination does not have any additional
effect on the reduction of cH2AX foci or an increase in
negative cells.
We have used, as many other laboratories do, the
standard cH2AX indirect immunofluorescence assay
and have seen foci in HGPS cells. However, in
addition surprisingly we found that zoledronic acid
and IGF-1 increase the number of cH2AX foci,
although not significantly at the 99.9% CI but the
increase was around 20% more cells with DNA
damage foci. The cH2AX DNA damage assay is
somewhat flawed since it analyses a marker of DNA
damage and as such is indirect; thus there is a concern
that there still may be DNA damage present that is
unmarked by cH2AX or is repairing inefficiently. In
order to investigate further actual DNA damage we
performed COMET assays that reveal the extent of
actual breaks in the cells’ DNA. Cells encapsulated
within agarose were treated to alkaline unwinding and
denaturation of DNA and subjected to electrophoresis
to allow the broken DNA to move through the agarose.
Comets were stained with SYBR Gold and analysed
using a Zeiss Metafer system running CometScan
analysis software. The graph in Fig. 7 displays relative
frequencies of Tail Moments (%DNA in tail 9 tail
length in lm) for each treatment arranged in order of
effectiveness in reducing strand breaks (i.e. small tail
moments) compared with the untreated sample. Most
importantly the COMET analyses have revealed that
the cH2AX DNA damage foci seen after zoledronic
acid and IGF-1 treatment are not actual. This puts
doubt over the c-H2AX assay, especially in HGPS
studies and argues that COMET assays should always
be performed when analysing the ability of cells to
repair their DNA. Rapamycin was by far the best drug
at improving the ability of HGPS cells to repair their
damaged DNA, with NAC and zoledronic acid in
combination with pravastatin also doing well.
123
Biogerontology (2018) 19:579–602 593
In
te
rio
r t
el
om
er
es
 (%
)
2D
D 
Un
tre
ate
d
2D
D 
+ Z
ole
dr
on
ic 
ac
id
0
20
40
60
80
100
n.s.
In
te
rio
r t
el
om
er
es
 (%
)
2D
D 
Un
tre
ate
d
AG
01
97
2 U
ntr
ea
ted
AG
01
97
2 +
 FT
I-2
77
0
20
40
60
80
100
********
***
In
te
rio
r t
el
om
er
es
 (%
)
2D
D 
Un
tre
ate
d
AG
01
97
2 U
ntr
ea
ted
AG
01
97
2 +
 Pr
av
as
tat
in
0
20
40
60
80
100
********
n.s.
In
te
rio
r t
el
om
er
es
 (%
)
2D
D 
Un
tre
ate
d
AG
01
97
2 U
ntr
ea
ted
AG
01
97
2 +
 Zo
led
ro
nic
ac
id
0
20
40
60
80
100
********
n.s.
In
te
rio
r t
el
om
er
es
 (%
)
2D
D 
Un
tre
ate
d
AG
01
97
2 U
ntr
ea
ted
AG
01
97
2 +
 R
ap
am
yc
in
0
20
40
60
80
100
n.s.****
****
In
te
rio
r t
el
om
er
es
 (%
)
2D
D 
Un
tre
ate
d
AG
01
97
2 U
ntr
ea
ted
AG
01
97
2 +
 N
-ac
ety
l-L
-cy
ste
ine
0
20
40
60
80
100
********
n.s.
In
te
rio
r t
el
om
er
es
 (%
)
2D
D 
Un
tre
ate
d
AG
01
97
2 U
ntr
ea
ted
AG
01
97
2 +
 FG
0
20
40
60
80
100
********
n.s.
In
te
rio
r t
el
om
er
es
 (%
)
2D
D 
Un
tre
ate
d
AG
01
97
2 U
ntr
ea
ted
AG
01
97
2 +
 PZ
0
20
40
60
80
100
********
n.s.
In
te
rio
r t
el
om
er
es
 (%
)
2D
D 
Un
tre
ate
d
AG
01
97
2 U
ntr
ea
ted
AG
01
97
2 +
FP
Z
0
20
40
60
80
100
********
n.s.
a b c
d e f
g h i
Control HGPS HGPS + FPZ
123
594 Biogerontology (2018) 19:579–602
Discussion
The study described here was initiated to test different
drugs purported to be of clinical use in a range of
genome organisational assays namely—interphase
chromosome positioning, DNA halo assays asking
questions around genomic attachment to a nucle-
oskeleton and DNA damage quantification through
cH2AX foci and COMET analyses. Mehta et al.
(2011) demonstrated that chromosome 18 is located in
an interior position in interphase nuclei of senescent
HGPS cells and it was revealed that after treatment
with FTI-277 alone and together with GGTI-2147,
chromosome 18 was repositioned from an internal
location to a peripheral one (Mehta et al. 2011). We
also demonstrated in this present study that chromo-
some 18 occupies an interior location in proliferating
untreated HGPS nuclei. Using a combinations of
drugs, FTI-277 ? GGTI-2133 and FTI-
277 ? pravastatin ? zoledronic acid, resulted in relo-
cation of chromosome 18 from nuclear interior to
nuclear periphery within Ki-67 positive interphase
HGPS nuclei. We have demonstrated before that
chromosome X territories remain at the nuclear
periphery in all proliferating laminopathy cells anal-
ysed (Meaburn et al. 2007). Mehta et al. (2011) also
demonstrated that chromosome X localizes to the
nuclear periphery in HGPS cells and it was shown that
the X chromosome did not change nuclear position
after FTI-277 treatment alone nor with FTI-277 and
GGTI-2147 together (Mehta et al. 2011). Here in this
study we further demonstrated that chromosome X
occupies a peripheral location in a further proliferating
untreated HGPS cell line. Using combinations of
drugs, FTI-277 ? pravastatin ? zoledronic acid and
FTI-277 together with GGTI-2133 seem to result in a
relocation of chromosome X more towards the nuclear
periphery within proliferating cells but this was
insignificant. Interestingly, treatment of HGPS cells
with an FTI only showed that chromosome 18 moved
towards intermediate location, suggesting GGTI is
needed to remove geranyl moieties from the lamin.
From these experiments we would suggest that any
treatment containing FTI for HGPS will lead to a
positive reorganisation of the genome in interphase
nuclei. This is reassuring since the latest active drug
trial for HGPS children contains FTI (Lonafarnib) in
combination with the rapalogue Everolimus (https://
clinicaltrials.gov/ct2/show/NCT02579044).
Also from this study, it is clear that FTI-277,
pravastatin, rapamycin, IGF-1 and all three combina-
torial treatments improve the ratio of total area of
DNA halo to residual nucleus suggesting that the
amount of DNA within the nucleus, attached to
structure within it has been improved by these drug
treatments.
There has to be a question mark over cH2AX foci
assays since DNA damage highlighted in the DNA
damage foci assay (and indirectly from DNA halos)
appears not be to be real since when employing the
COMET assay there was no DNA damage apparent.
This was especially concerning for the zoledronic acid
treatment. However, we would suggest that consider-
ation be taken with any treatments using zoledronic
acid since it is used as a cancer treatment to arrest
proliferating cells through DNA damage response and
we are not the first to see DNA damage foci in cells
treated with it (Iguchi et al. 2007; Ohnuki et al. 2012)
and a further, deeper investigation of the potential of
zoledronic acid to promote DNA damage is called for
although there is a study which implies zoledronic acid
attenuates DNA damage (Misra et al. 2015).
Rapamycin is the other drug being used in combi-
nation with FTI in the new clinical trial for HGPS. In
this study rapamycin was the best drug for permitting
DNA damage in the HGPS cells to be repaired. This
means that the two top performing drugs that we have
found in our panel of nine treatments with four assays
are being given to children with HGPS. The only point
of concern could be that rapamycin impacts on the
interaction of telomeres with the nucleoskeleton—this
also warrants further investigation. However, it has
been suggested that analogues of rapamycin such as
temsirolimus might substitute for rapamycin given
bFig. 5 Comparisons of the fraction of telomeres found in the
residual nuclei of DNA Halo preparations of HGPS before and
after drug treatments. Images of fixed control and HGPS DNA
halos stained with both DAPI (blue) and Cy3 (red) telomeric
PNA probes were captured at 9100 magnification. Residual
nuclei were delineated and the fraction of telomeres determined
inside and outside of the residual nuclei. Results for the
treatments are shown as a 2DD with zoledronic acid, b FTI-277,
c pravastatin, d zoledronic acid, e rapamycin, f N-acetyl-L-
cysteine, g FTI-277 and GGTI-2133, h pravastatin and
zoledronic acid and i FTI-277, pravastatin and zoledronic acid.
The proportion of interior telomeres is expressed as a percentage
of the total number of telomeres present. Error bars repre-
sent ± SEM. Scale bar = 10 lM
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that there are some potential drawbacks to using
rapamycin (Gabriel et al. 2016).
Potential drugs for treatment of HGPS
Since the original studies leading to the choices of FTI,
Pravastatin, Zoledronic Acid and Rapamycin, other
drugs have come to the fore as potential treatments for
HGPS. These include drugs such as the anti-oxidant
sulforaphane and the proteasome inhibitor MG132
which both encourage autophagy, helping to clear the
toxic progerin from HGPS cells (Gabriel et al. 2017;
Harhouri et al. 2017). Another combinatorial treat-
ment with all-trans retinoic acid, another inducer of
autophagy, in combination with rapamycin normalises
HGPS cells by reducing progerin, farnesylated pre-
lamin A, and DNA damage foci (Pellegrini et al.
2015).
The anti-diabetic drug metformin is also hailed as a
treatment for HGPS as well as an anti-ageing
treatment—given that diabetic patients on metformin
live longer than the control group (Bannister et al.
2014). Metformin treatment of HGPS cells results in
the down-regulation of progerin expression (Egesipe
et al. 2016; Park and Shin 2017). Methylene blue is
another anti-oxidant and potential anti-ageing product
that seems to have great potential in treating HGPS
(Xiong et al. 2017). Other successful compounds that
reduce reactive oxygen species in HGPS include the
rho-associated protein kinase (ROCK) inhibitor—Y-
27632, reducing DNA damage, improving nuclear
shape and restoring mitochondrial function (Kang
et al. 2017).
Interestingly, a compound called NAT10 or
Remodelin (Larrieu et al. 2014) also improves nuclear
morphology in HGPS cells, as well as a reduction in
cH2AX foci but also improves chromatin organisation
as assessed by staining with anti-H3K9me3 antibodies
which is in common with the study using all-trans
retinoic acid and rapamycin (Pellegrini et al. 2015).
Nucleolar structure is also improved, as has been
shown for FTI as well (Mehta et al. 2010b).
Most excitingly, new drug possibilities have been
found that could substitute for FTIs, given that two
mono-amino pyrimidines inhibit farnesylation by
inhibiting farnesyl pyrophosphate synthase and farne-
syl transferase (Blondel et al. 2016). Vitamin D
receptor has been found to be linked to premature
ageing (Keisala et al. 2009), and using 1a,
25-dihydroxyvitamin D3 improves a range of HGPS
phenotypes (Kreienkamp et al. 2016).
Telomere anchorage by the NM in normal
and HGPS fibroblasts before and after drug
treatment in the DNA halo assay
Telomeres are shortened with each cell division due to
the end replication problem, once telomere length
reaches a critical length, the cells enter replicative
senescence (Stewart and Weinberg 2006). It has been
demonstrated that such eroded telomeres trigger DNA
damage checkpoint responses which in turn leads to
this irreversible G1/S cell cycle arrest (di Fagagna
et al. 2003). In light of these facts, we thought it
pertinent to examine and compare telomere interac-
tions with the nucleoskeleton in control (2DD) and
typical HGPS (AG01972) HDFs by coupling the DNA
halo preparation with telomere PNA FISH (Bridger
and Lichter 1999), using combination of drug treat-
ments. We have demonstrated that telomere anchorage
with the nucleoskeleton in AG01972 HGPS line,
which produces a mutant form of lamin A (progerin)
is severely perturbed. More than 20% of telomeres
were found outside residual nuclei. De Vos et al.
(2010) reported that in HDFmut/mut cells, telomere
mobility is higher and less confined compared with
normal fibroblasts. However, intriguingly in their
experiments, it was exhibited that telomere movement
appeared more restricted in HGPS cells (De Vos et al.
2010). Remarkably, treatment of HGPS cells with FTI
is able to increase telomere mobility (De Vos et al.
2010). It is known that progeria cells have shorter
telomeres (Allsopp et al. 1992) and chromosomal
aberrations in the setting of telomere dysfunction were
shown to be triggered by progerin expression in HGPS
cFig. 6 Comparison of the fraction of HGPS fibroblasts
displaying DNA damage cH2AX foci before and after drug
treatments. Fixed control and HGPS cells (untreated and treated)
were subjected to indirect immunofluorescence with a primary
antibody recognising phosphorylated histone H2AX a DNA
damage marker (green). Distributions of foci were placed in
three patterns negative, 1–2 foci and multiple foci and
percentages plotted as bar charts a FTI-277, b pravastatin,
c zoledronic acid, d rapamycin, e IGF-1, f N-acetyl-L-cysteine,
g FTI-277 and GGTI-2133, h pravastatin and zoledronic acid
and i FTI-277, pravastatin and zoledronic acid. Error bars
represent ± SEM. Scale bar = 10 lm
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cells (Benson et al. 2010). Rippe’s group (2009)
showed that shorter telomeres have increased telomere
mobility in a telomerase negative human cell line
(Jegou et al. 2009) and in line with our findings which
has demonstrated that telomere binding to the nucle-
oskeleton is reduced in HGPS cells. Gonzalez-Suarez
et al. (2009) demonstrated that the accumulation of
farnesylated lamin A is concomitant with a migration
of telomeres towards the nuclear periphery (Gonzalo-
Suaraz et al. 2009). Raz et al. (2008) reported that
association of telomeric repeats with lamina intranu-
clear structure is increased in cells expressing lamin
mutants (Raz et al. 2008). It can be suggested that for
the correct localization of telomeres within the
nucleus, intranuclear lamins play a vital role (De
Vos et al. 2010). Whereas, telomere-nucleoskeleton
interactions in control cell line (2DD) reveal that
approximately 93–94% of telomeres were found
within residual nuclei. The results are also in agree-
ment with an earlier study which shows that at least
80% of telomeric DNA is attached to this structure (de
Lange 1992). The findings also confirm previous
HALO-FISH experiments using telomere-specific
probes (Luderus et al. 1996). Zoledronic acid treated
2DD cells showed that 95–96% of telomeres were
found within the residual nucleus which does not
change statistically the telomere location. From this
study, it is clear that FTI-277, pravastatin, zoledronic
acid, N-acetyl-L-cysteine and all three combination
treatments, FG, PZ, FPZ, have a positive effect on
anchoring the genome to the nucleoskeleton in
AG01972 cell line. On the contrary, rapamycin treated
AG01972 cells give rise to a reduction of anchorage of
telomeres to the nucleoskeleton having approximately
76–77% of telomeres in the residual nuclei but does
not show any significant difference compared with
untreated AG01972 cells.
In conclusion, the results of this study have
potentially far-reaching implications for the treatment
of sufferers with HGPS. For instance, of the drugs
currently used in clinical trials, only pravastatin led to
a reduction in DNA damage, and not when in
combination as used in the trials. FTIs do not
significantly reduce DNA damage despite having well
recognised improvements to nuclear shape. Rapamy-
cin performed well with respect to aiding HGPS cells
repair DNA damage, but was not able to restore
normal genome organisation. Thus, it could be envi-
sioned that rapamycin could be used in combination
with an FTI. From the analyses in this study it is clear
that further studies should concentrate more on the
effects of drug treatments on other nuclear proteins,
genome organisation, and gene expression in HGPS
fibroblasts rather than just assessing nuclear shape.
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